Mestag Therapeutics is fast-growing biotech that is building something special – a company using unparalleled insight into the role of fibroblast populations in disease to deliver impactful precision medicines. We founded Mestag in 2020 to pioneer new medicines for people affected by inflammatory disease and cancer. Our leadership team includes biotech entrepreneurs and seasoned global drug discovery experts focused on translating exciting biology into meaningful therapies for patients.
We focus on activated fibroblast populations and their role in influencing the immune system in disease. Our founder team comprises leading experts in the fields of inflammatory disease, oncology, computational biology and fibroblast biology from the University of Oxford, Harvard, Broad Institute and Cold Spring Harbor Laboratory, including the current President of AACR.
We are progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. We are also collaborating with Janssen Biotech, Inc to discover new targets for inflammatory disease and cancer. Mestag’s investors include leading global biotech investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. The company is headquartered in Cambridge, UK.
Our team shares a common purpose and puts patients at the centre of our work. Our values of trust and integrity, connection and togetherness, energy and tenacity, and ingenuity and excellence fuel our passion for science, and have created a strong culture of purpose and delivery. We are looking for proactive, creative and positive team players to help build and shape our company into a world leader.